Jamie Bakkum-Gamez, MD, associate professor of obstetrics and gynecology and Gynecologic oncologist at Mayo Clinic, discusses her research on developing an early detection test for endometrial cancer.
Jamie Bakkum-Gamez, MD, associate professor of obstetrics and gynecology and Gynecologic oncologist at Mayo Clinic, discusses her research on developing an early detection test for endometrial cancer.
Transcript
What sort of novel approaches did you research to assist in the early detection of endometrial cancer?
One of the projects that I’ve been working on from the research side of things since I came on staff at Mayo clinic is the development of an early detection test for endometrial cancer.
In gynecology, we’ve had huge success when it comes to screening for cervical cancer with the PAP test and PAP+HPV, but we do not have a screening test for endometrial cancer. Endometrial cancer is now the most common gynecologic malignancy that we care for in the United States. One in 50 women will develop an endometrial cancer and when they come in to see me, oftentimes the question that I get asked is, “My pap smear was normal…how could I have cancer and have a normal pap smear?”
Well the pap smear is not a test that is designed to pick up endometrial cancer. In fact, the sensitivity of a PAP test to pick up abnormal cells that indicate endometrial cancer up inside the uterus is only about 30%. But we know that there are molecular markers that are shed from cancers into other biospecimens— whether it’s peripheral blood, or other downstream biospecimens.
So, the biospecimen that we have been focusing our research on is that of the vaginal pool. The vaginal pool is defined as everything that comes from up in the female reproductive tract and flows down into the vagina. This could be fluid and material that comes from the fallopian tubes, maybe even the ovaries— there’s actually some data out there that suggests that mutations that arise in ovarian cancer can actually be detected in samples from the vagina and cervix, so we know that there is some downstream targeting of that. Also, fluid from the endometrium cavity, the cervix and the vagina. So, all of that is what’s in the vaginal pool.
What we’ve been doing is trying to design an early detection test using a tampon as the tool for collecting that biospecimen. In that biospecimen we look for molecular markers such as methylation or mutations. Similar to the most recent paradigm shift in colorectal cancer screening, which is that of the stool-based test called cologuard, we aim to develop a multi-panel/multi-marker test that will pick up endometrial cancer or endometrial cancer precursers. [This would] allow women to have the diagnosis earlier, ideally, and allow better access to care because this would be a test or a specimen that could be collected from the comfort of our patient’s own bathroom.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More